The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations – the Lung Cancer Mutation Consortium (LCMC2)

PURPOSE: Multiplex genomic profiling is standard of care for patients with advanced lung adenocarcinomas. The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional effort to identify and treat oncogenic driver events in patients with lung adenocarcinomas. PATIENTS AND METHODS: Sixteen U.S....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Aisner, Dara L., Sholl, Lynette M., Berry, Lynne D., Rossi, Michael R., Chen, Heidi, Fujimoto, Junya, Moreira, Andre L., Ramalingam, Suresh S., Villaruz, Liza C., Otterson, Gregory A., Haura, Eric, Politi, Katerina, Glisson, Bonnie, Cetnar, Jeremy, Garon, Edward B., Schiller, Joan, Waqar, Saiama N., Sequist, Lecia V., Brahmer, Julie, Shyr, Yu, Kugler, Kelly, Wistuba, Ignacio I., Johnson, Bruce E., Minna, John D., Kris, Mark G., Bunn, Paul A., Kwiatkowski, David J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7008001/
https://ncbi.nlm.nih.gov/pubmed/29217530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2289
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky